THE ARIZONA
SURGELINE

ARIZONA SURGE LINE
PROTOCOL FOR TRANSFERS WITH REMDESIVIR

DRAFT

Background

The FDA has granted an Emergency Use Authorization for the use of remdesivir to treat severe cases of COVID-19. Remdesivir supply is currently being distributed by the federal government to state governments which then distribute doses to health departments and hospitals caring for patients with COVID-19.

Protocol

In order to ensure standard and equitable care for patients being transferred through the Arizona Surge Line, the following is the formal protocol:

1. Patients started on Remdesivir in the originating facility will be sent to the destination facility with the remaining doses of a 5-day course.
    - Patients who are started on Remdesivir from the originating facility who are not sent with the complete regimen are not guaranteed continued dosing at the receiving facility.
2. The patient transport service must be able to ensure proper medication storage and safety during transport.
    - In the concentrated solution, remdesivir must be kept at refrigerated temperatures (2-8 degrees Celsius) until use; in the lyophilized powder form, it must be kept at controlled room temperature (below 30 degrees Celsius until use).
    - Both the concentrated solution and lyophilized powder form are stored in glass containers. This is unlikely to be a problem with air transport if remdesivir is not being actively infused during transport.

Further resources

NIH COVID-19 Treatment Guidelines
FDA Emergency Use Authorization for the use of remdesivir